A study led by researchers at the MD Anderson Cancer Center at the University of Texas found that hormone receptor-positive (HR +) human epidermal growth factor receptor 2-negative (HER2-) metastatic breasts were treated with ribociclib and endocrine therapy overall in postmenopausal patients. Cancer that has been shown to have a significant life-prolonging effect. This is the first demonstration of the survival advantage of front-line CDK4 / 6 inhibitors in postmenopausal patients with HR + / HER2-advanced breast cancer.
In a randomized phase III MONALEESA-2 trial, a 63.9-month survival advantage with the front-line ribociclib, CDK4 / 6 inhibitor, and aromatase inhibitor letrozole compared to 51.4 months with hormone therapy alone. Was shown. The estimated 6-year survival rate was 44.2% for ribociclib, compared to 32% for placebo. Gabriel Hortobagyi, MD, a professor of breast oncology, presented the findings at the European Society for Medical Oncology (ESMO) Conference 2021.
“These findings are based on previous MONALEESA trials that achieved a life-prolonging effect with the addition of ribociclib,” said Hortobagyi. “I highly encourage that metastasis chest Cancer patients Treatment options It prolongs survival, delays chemotherapy treatment and maintains their quality of life. “
A previously reported MD Anderson study showed that ribociclib and letrozole improved progression-free survival in postmenopausal women with HR + metastatic breast cancer in the MONALEESA-2 trial, but the combination was advanced HR. + Reported improved progression-free survival and overall survival in premenopausal breast patients. According to the results of the MONALEESA-7 trial, cancer.
The international double-blind study, MONALEESA-2, enrolled 668 postmenopausal women. Advanced breast cancer At 223 test facilities in 29 countries. They were randomized to receive either ribociclib and letrozole, or letrozole and placebo. No one was treated for a previously advanced illness. The study participants were 82.2% white, 7.6% Asian, 2.5% black, and 7.6% others.
The median follow-up was 79.7 months, and the time to first chemotherapy treatment was 50.6 months in patients receiving ribociclib, compared with 38.9 months in placebo.
No new safety signals were observed and the adverse events were consistent with previously reported Phase III MONALEESA study results.
“Given these results, the combination of a CDK4 / 6 inhibitor and an aromatase inhibitor should be the standard first-line treatment for the majority of patients with advanced hormone receptor-positive breasts. cancer“These findings can affect most women diagnosed. Metastatic breast cancer.. “
This study was sponsored by Novartis Pharmaceuticals Corporation, which sells ribociclib (Kiscari). Hortobagyi is a paid consultant for Novartis, and MD Anderson received funding from Novartis to carry out this study. A complete list of collaborators and their disclosures is included in the abstract.
University of Texas MD Anderson Cancer Center
Quote: Ribociclib added to endocrine therapy was obtained from https://medicalxpress.com/news/2021-09-ribociclib-added-endocrine-therapy-survival on September 19, 2021 after menopause. Extends the survival of the patient (September 19, 2021). html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Adding ribociclib to endocrine therapy prolongs the survival of postmenopausal patients with metastatic breast cancer
Source link Adding ribociclib to endocrine therapy prolongs the survival of postmenopausal patients with metastatic breast cancer